G
Gregor Verhoef
Researcher at Katholieke Universiteit Leuven
Publications - 395
Citations - 30922
Gregor Verhoef is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 73, co-authored 389 publications receiving 29031 citations. Previous affiliations of Gregor Verhoef include The Catholic University of America & University of Perugia.
Papers
More filters
Journal ArticleDOI
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more
TL;DR: Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Journal ArticleDOI
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more
TL;DR: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
Journal ArticleDOI
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools,Jan Cools,Daniel J. DeAngelo,Jason Gotlib,Elizabeth H. Stover,Robert D. Legare,Robert D. Legare,J. E. Cortes,Jeffrey L. Kutok,Jennifer J. Clark,Ilene Galinsky,James D. Griffin,Nicholas C.P. Cross,Ayalew Tefferi,James M. Malone,Rafeul Alam,Stanley L. Schrier,Janet L. Schmid,Michal G. Rose,Peter Vandenberghe,Gregor Verhoef,Marc Boogaerts,Iwona Wlodarska,Hagop M. Kantarjian,Peter Marynen,Steven Coutre,Richard Stone,D. Gary Gilliland +27 more
TL;DR: The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
Journal ArticleDOI
Stromal gene signatures in large-B-cell lymphomas
Georg Lenz,George E. Wright,Sandeep S. Dave,Wenming Xiao,Jonathan D. Powell,Hong Zhao,Weihong Xu,Bruce K. Tan,Neta Goldschmidt,Javeed Iqbal,Julie M. Vose,Martin Bast,Kai Fu,Dennis D. Weisenburger,Timothy C. Greiner,James O. Armitage,Alastair H. Kyle,Lorraine May,Randy D. Gascoyne,Joseph M. Connors,Gunhild Trøen,Harald Holte,Stein Kvaløy,Daan Dierickx,Gregor Verhoef,Jan Delabie,Erlend B. Smeland,Pedro Jares,A. Martinez,Armando López-Guillermo,Emili Montserrat,Elias Campo,Rita M. Braziel,Thomas P. Miller,Lisa M. Rimsza,James R. Cook,Brad Pohlman,John Sweetenham,Raymond R. Tubbs,Richard I. Fisher,Elena Hartmann,Andreas Rosenwald,German Ott,German Ott,H-K Muller-Hermelink,D Wrench,T. A. Lister,Elaine S. Jaffe,Wyndham H. Wilson,Wing C. Chan,Louis M. Staudt +50 more
TL;DR: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.
Journal ArticleDOI
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg,Gert J. Ossenkoppele,Wim L.J. van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Johan Maertens,Mojca Jongen-Lavrencic,Marie von Lilienfeld-Toal,Bart J. Biemond,Edo Vellenga,Marinus van Marwijk Kooy,Leo F. Verdonck,Joachim Beck,Hartmut Döhner,Alois Gratwohl,Thomas Pabst,Gregor Verhoef +18 more
TL;DR: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional doses, without additional toxic effects.